Table 2.
Prognostic factors for overall survival
|
Patients
(n) |
Number of responders § |
Median OS
(months) |
p | |
|---|---|---|---|---|
|
Age | ||||
| ≤ 65 years |
24 |
10 |
21.9 |
0.85 |
| > 65 years |
26 |
10 |
24.5 |
|
|
Primary Malignancy | ||||
| Hematological |
27 |
12 |
11.67 |
0.83 |
| Solid |
23 |
8 |
17.97 |
|
|
azacitidine dose | ||||
| 75 mg/smq/7 days |
36 |
12 |
16.7 |
0.31 |
| 100 mg/day 10 days |
4 |
3 |
14.2 |
|
| 100 mg/day 5 or 7 days |
10 |
5 |
16.2 |
|
|
WHO diagnosis | ||||
| RCMD |
12 |
9 |
30.9 |
|
| RAEB 1/2 |
22 |
7 |
16.8 |
0.02 |
| AML |
16 |
4 |
8.5 |
|
|
Karyotype | ||||
| Normal |
8 |
8 |
27.7 |
|
| Single or double abnormality |
9 |
3 |
11.6 |
0.66* |
| Complex |
20 |
9 |
16.2 |
|
|
Chromosome 7 abnormalities | ||||
| Yes |
14 |
8 |
11.63 |
0.72 |
| No |
33 |
12 |
17.96 |
|
|
Transfusion dependence | ||||
| Yes |
26 |
10 |
11.6 |
0.38 |
| No |
24 |
10 |
21.9 |
|
|
Previous Treatment | ||||
| No pre-treatment |
40 |
17 |
27.7 |
0.0001 |
| ESA |
4 |
2 |
16.2 |
|
| Hydroxyurea |
2 |
1 |
9.5 |
|
| Conventional Chemotherapy |
4 |
0 |
5.4 |
|
|
HCT-CI
#
| ||||
| 0–2 |
5 |
0 |
8.8 |
|
| 3 |
19 |
6 |
8.5 |
0.2 |
| 4 |
6 |
4 |
53.7 |
|
| >5 | 9 | 4 | 16.2 | |
* The difference in overall survival between normal and aberrant karyotype was however statistically significant restricting the analysis to t-AML patients (Figure 3A).
§ Number of patients achieving CR, PR or HI; # HCT-CI data were available for 39 patients.